Table 1.
Participant baseline characteristics, overall and anti-TNF utilisation status
| Full sample (n=8502) |
anti-TNF non-users (n=8186) |
New episode of anti-TNF users (n=121)* |
||||
|---|---|---|---|---|---|---|
| (n) | (%) | (n) | (%) | (n) | (%) | |
| Age mean (SD) | 76 (8) | 76 (8) | 73 (6) | |||
| Female | 6111 | 72 | 5891 | 72 | 83 | 69 |
| Caucasian | 7708 | 91 | 7408 | 91 | 118 | 98† |
| Region | ||||||
| Northeast | 2104 | 25 | 2044 | 25 | 29 | 24 |
| Southeast | 2385 | 28 | 2278 | 28 | 40 | 33 |
| Midwest | 2004 | 24 | 1922 | 24 | 28 | 23 |
| Rocky Mountains | 239 | 3 | 234 | 3 | <11† | – |
| Southwest | 802 | 9 | 768 | 9 | 12 | 10 |
| Pacific‡ | 968 | 11 | 940 | 12 | <11† | – |
| Urban/suburban | 6426 | 76 | 6192 | 76 | 87 | 72 |
| Medicaid coverage | 1915 | 23 | 1885 | 23 | <11† | – |
| Polypharmacy (≥5 drugs) | 4920 | 62 | 4719 | 62 | 72 | 60 |
| Charlson Index Mean (SD) | 1 (2) | 1 (2) | 1 (2) | |||
| Gastroenterologist visit | 4392 | 52 | 4158 | 51 | 76 | 63 |
| >1 endoscopy | 1183 | 14 | 1141 | 14 | 20 | 17 |
| IBD surgery | 211 | 3 | 199 | 2 | <11† | – |
| Hospitalisations mean (SD) | 1 (1) | 1 (1) | 1 (1) | |||
*New anti-TNF utilisers initiated therapy after the completion of the baseline period; bivariate analyses is the comparison of new episodes of use to non-use (n=8307); prevalent anti-TNF utilisers were already receiving therapy during the baseline study period (n=195) and were excluded from anti-TNF non-users group (n=8186).
†Cell size is too small and requires suppression as part of the data use agreement.
‡Includes Hawaii, Alaska and Puerto Rico.
IBD, inflammatory bowel disease; TNF, tumour necrosis factor.